Patients harboring *BRCA1* or *BRCA2* (*BRCA1*/2) gene mutations account for approximately 5% of all breast cancers \[[@B1]\] and approximately 15--20% of hereditary breast cancers \[[@B2]\]. The prevalence of *BRCA1*/*2* germline mutations is considerably higher among certain ethnic groups (e.g., Ashkenazi Jews) and geographic areas. Population-specific and recurrent mutations have been described in Iceland, The Netherlands, Sweden, Norway, Germany, France, Spain, Canada and other countries of eastern and southern Europe. According to recent estimates, 55--65% of women who inherit a *BRCA1* mutation and around 45% of women who inherit a *BRCA2* mutation will develop breast cancer by the age of 70 years \[[@B3]\]. While there are no definitive guidelines on the optimal chemotherapy for these patients, there is increasing evidence of enhanced sensitivity to specific systemic agents in this patient population. Recent clinical data show high response rates in patients with *BRCA*-associated breast cancer treated with platinum therapy \[[@B4]\], and the inclusion of platinum-containing regimens in the treatment of these patients has recently been supported by the Advanced Breast Cancer 2 panel \[[@B7]\].

A promising area of clinical research is the investigation of PARP inhibitors in treating *BRCA1*/*2*-associated tumors. Initial data with olaparib \[[@B8]\] and its subsequent approval for treatment of recurrent *BRCA*-mutated ovarian cancer \[[@B9]\] support the unique sensitivity of these tumors to PARP inhibition via an interaction characterized by synthetic lethality. Ongoing research with PARP inhibitors as monotherapy, and as agents that potentiate chemotherapy, seeks to improve outcomes for patients with advanced breast cancer ([Table 1](#T1){ref-type="table"} \[[@B12]\]).

###### **Poly(ADP-ribose) polymerase inhibitors in clinical development for breast cancer.**

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **PARP inhibitor**              **Pharmaceutical company**        **Investigational phase**
  ------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  Veliparib (ABT-888)             AbbVie                            Phase III:\
                                                                    -- Neoadjuvant setting in combination with carboplatin/paclitaxel in triple-negative *BRCA1*/*2*-mutated metastatic breast cancer\
                                                                    Phase II/III:\
                                                                    -- Combination therapy in germline *BRCA1*/*2*-mutated metastatic breast cancer

  Olaparib (AZD2281)              AstraZeneca                       Phase III:\
                                                                    -- Adjuvant treatment in germline *BRCA1*/*2*-mutated high-risk, *HER2*- primary breast cancer\
                                                                    -- Advanced setting monotherapy in germline *BRCA1*/*2*-mutated breast cancer

  Niraparib (formerly MK-4827)    Tesaro                            Phase III:\
                                                                    -- Advanced setting in germline *HER-, BRCA1/2*-mutated breast cancer

  Talazoparib (BMN 673)           Medivation                        Phase III:\
                                                                    -- Advanced setting monotherapy in germline *BRCA1*/*2*-mutated breast cancer\
                                                                    Phase II:\
                                                                    -- Advanced setting *BRCA1*/*2* wild-type, triple-negative breast cancer and homologous recombination deficiency\
                                                                    -- Advanced setting *BRCA1*/*2*-mutated breast cancer\
                                                                    -- Advanced setting in germline *BRCA*-intact breast cancer\
                                                                    -- Neoadjuvant setting in *BRCA1*/*2*-mutated breast cancer

  Rucaparib (formerly AG 14699)   Clovis Oncology                   Phase II:\
                                                                    -- Advanced setting in patients with known germline *BRCA1*/*2*-mutated solid tumors\
                                                                    -- Adjuvant setting in triple-negative breast cancer or germline *BRCA1*/*2*-mutated breast cancer

  CEP-9722                        Teva Pharmaceuticals Industries   Phase II:\
                                                                    -- Advanced setting in solid tumors
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PARP: Poly(ADP-ribose) polymerase.

Adapted with permission from Livraghi *et al*. *BMC Med.* (2015) \[[@B12]\].

PARP-1 and -2, the primary targets of veliparib, belong to the PARP family of proteins. They are involved in diverse cellular processes including detection and repair of various types of DNA damage, such as single- or double-strand DNA breaks \[[@B13]\]. Their role in DNA damage repair is complex, multifaceted and depends on the specific type of damage and associated repair mechanisms ([Figure 1](#F0001){ref-type="fig"} \[[@B13]\]). DNA damage resulting in single-strand breaks (SSBs), base mismatch or intrastrand cross-links are repaired by mechanisms including single-strand break repair (SSBR), base excision repair, mismatch repair and nucleotide excision repair. Double-strand break (DSB) repair includes homologous recombination and nonhomologous end joining. Of the 17 members of the PARP family that have been discovered, PARP1--3 have DNA-binding domains and are catalytically activated upon interaction with DNA damage \[[@B14]\]. When damage is recognized, ADP-ribosylation results in recruitment of repair factors, many of which contain domains that mediate interactions with polymers of ADP-ribose (PAR) \[[@B17],[@B18]\]. The ADP-ribosylation of DNA-associated factors such as histones causes a relaxed chromatin state that enables access of DNA repair proteins to the DNA damage \[[@B19]\], thereby promoting repair \[[@B16]\]. During SSBR, release of PARP1 from the SSB is required for repair to proceed. This is mediated by the automodification of PARP1 with PAR.

![**Model of poly(ADP-ribose) polymerase role in DNA damage repair and effect of poly(ADP-ribose) polymerase inhibition -- *BRCA* mutation synthetic lethality.**\
**(A)** On detection of a single-strand break, the recruitment and activation of poly(ADP-ribose) polymerase (PARP) leads to single-strand break repair via polymers of ADP-ribosylation of histones and chromatin-remodeling enzymes, autoPARylation of PARP and recruitment of PARP-dependent DNA repair proteins. Repaired DNA can subsequently undergo replication, resulting in the survival of the cell. **(B)** When PARP inhibitors are present, PARP-dependent repair systems are not activated due to catalytic inhibition and/or direct trapping. This results in replication fork stalling during DNA replication, and the stalled replication fork eventually collapse, creating DSBs. In cells where homologous recombination is not impaired (*BRCA*-wild-type), DSBs are repaired and replication may restart, resulting in cell survival. However, in *BRCA*-deficient cells where hazard ratio is impaired, DSB cannot be efficiently repaired and DSB accumulates, resulting in cell death.\
DSB: Double-strand break; HR: Homologous recombination; RF: Replication fork; SSB: Single-strand break.\
Adapted with permission from Livraghi *et al*. *BMC Med.* (2015) \[[@B12]\]. No changes were made.](fon-13-307-g1){#F0001}

Preclinical evidence has revealed synergistic activity of PARP inhibitors with DNA-alkylating and platinum agents \[[@B20]\], as well as topoisomerase I inhibitors \[[@B21]\]. Since the repair pathway(s) for lesions caused by each of these classes of agents differ, the mechanism of action underlying the potentiation of cytotoxic activity is likely to be class specific and dependent on the genetic and disease background \[[@B22],[@B23]\]. The capability of PARP inhibitors to potentiate the clinical activity of DNA-damaging chemotherapy is being actively investigated in clinical trials in a number of different indications, including breast, ovarian, colorectal, sarcoma and lung cancers, with various concomitant DNA-damaging therapies.

Veliparib {#S0001}
=========

Veliparib (ABT-888) is an investigational, oral PARP inhibitor being evaluated in Phase I--III clinical trials, including Phase III studies in non-small-cell lung cancer (NSCLC), ovarian cancer and breast cancer. Veliparib is orally bioavailable and readily crosses the blood--brain barrier. As a single agent, veliparib significantly diminishes PAR levels in tumor biopsies following a single dose of 25 mg or greater, and demonstrates good bioavailability at these doses \[[@B24]\]. A Phase I study of single-agent veliparib in patients with either *BRCA1*/*2*-mutated cancer, platinum-refractory ovarian cancer or basal-like breast cancer (*BRCA*-wild-type) reported by Puhalla *et al*. \[[@B25]\] defined the recommended Phase II dose (RP2D) as 400 mg twice daily (b.i.d.). Veliparib was well tolerated and demonstrated antitumor activity in *BRCA*-mutated and *BRCA*-wild-type tumors at the RP2D, with an overall response rate (ORR) and clinical benefit rate (CBR) in *BRCA*-mutated tumors of 40 and 68%, respectively \[[@B25]\]. Further evidence of veliparib\'s activity was observed in a Phase II study in persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in patients with a germline *BRCA1* or *BRCA2* mutation, as illustrated by an ORR of 26% (20% for platinum-resistant and 35% for platinum-sensitive patients) \[[@B26]\]. In this Phase II study, common toxicities (\>10%) included nausea, fatigue, vomiting and anemia.

Veliparib potentiates the antitumor activity of temozolomide (TMZ) and platinum-based chemotherapy in syngeneic and xenograft tumor models \[[@B20]\]. Veliparib strongly potentiates TMZ \[[@B20]\] in preclinical models that are sensitive or insensitive to TMZ monotherapy \[[@B27]\]. With respect to platinum agents, a previous study demonstrated mild *in vivo* potentiation of cisplatin with the PARP inhibitor CEP-6800 in a NSCLC xenograft model \[[@B28]\]. Consistent with these results, Donawho *et al*. demonstrated enhanced activity of cisplatin and carboplatin with veliparib in multiple models, including robust potentiation of these agents in breast xenograft models with *BRCA* loss of function \[[@B20]\]. In a separate study, veliparib also potentiated the efficacy of carboplatin or cisplatin in an small-cell lung cancer xenograft model \[[@B23]\]..

Following observation of activity in preclinical studies, Phase I and II trials evaluated veliparib in combination with platinum therapies, alkylating agents and topoisomerase inhibitors. In a dose--escalation study of veliparib plus carboplatin/paclitaxel (3-weekly dosing) in patients with multiple tumor types, promising antitumor activity was observed at the maximally administered oral doses, veliparib 120 mg b.i.d., paclitaxel 200 mg/m^2^ and carboplatin AUC 6 (breast cancer \[n = 14\]: three complete responses \[CR\], five partial responses \[PR\], ORR: 57%; lung cancer \[n = 16\]: one CR, five PR, ORR: 37.5%) \[[@B29]\]. The combination of veliparib plus carboplatin/paclitaxel was evaluated in a Phase II randomized, placebo-controlled study in NSCLC. Patients received placebo/veliparib 120 mg b.i.d. on days 1--7 plus carboplatin AUC 6 and paclitaxel 200 mg/m^2^ on day 3 of a 21-day cycle. The addition of veliparib resulted in improvements in progression-free survival (PFS) and overall survival (OS). Among all subjects (n = 53, placebo; n = 105, veliparib), median PFS was 4.2 months (95% CI: 3.1--5.6) and 5.8 months (95% CI: 4.2--6.1) for placebo and veliparib, respectively (hazard ratio \[HR\]: 0.74 (0.46--1.17); median OS was 9.1 months (95% CI: 5.4--12.3) and 11.7 months (8.8--13.7) for placebo and veliparib (HR: 0.80 \[0.54--1.18\]). Subgroup analyses suggested greater benefit from adding veliparib in patients with squamous cell histology. Among patients with squamous cell histology, median PFS was 4.1 months (95% CI: 2.8, not available) and 6.1 months (95% CI: 5.8--8.3) with placebo and veliparib, respectively (HR: 0.5 \[95% CI: 0.24--1.04\]); median OS was 8.4 months (95% CI: 5.0--12.9) and 10.3 months (95% CI: 8.3--13.2) with placebo and veliparib (HR: 0.71 \[95% CI: 0.41--1.23\]). Subgroup analyses also suggested a greater benefit of adding veliparib in smokers \[[@B30]\]. The tolerability profile of veliparib with carboplatin and paclitaxel was similar to that of carboplatin and paclitaxel alone. Of the treatment-emergent adverse events, neutropenia was slightly higher in the veliparib combination arm: 36 versus 29%, as was leukopenia: 11 versus 1%. No difference was observed in the incidence of grade 3/4 adverse events, including anemia, neutropenia and thrombocytopenia \[[@B31],[@B32]\].

A study of veliparib in combination with carboplatin in 28 patients (26 eligible) with *BRCA*-associated breast cancer established a maximum tolerated dose (MTD) of 150 mg veliparib and carboplatin AUC 5; the CBR was 71% and RR 57% in all enrolled patients \[[@B33]\]. Additional Phase I data in patients with breast cancer demonstrated promising antitumor activity with weekly dosing of carboplatin/paclitaxel in combination with veliparib \[[@B34]\]; the RP2D of veliparib was established as 150 mg b.i.d., with dose-limiting toxicities occurring at 150 mg b.i.d. (prolonged grade 2 thrombocytopenia) and 200 mg b.i.d. (grade 4 neutropenia). In another Phase I study, veliparib was active in patients with metastatic breast cancer, with the RP2D established as 250 mg b.i.d. veliparib and carboplatin AUC 5. Thrombocytopenia was the main toxicity observed \[[@B35]\]. In the I-SPY 2 adaptive Phase II trial, the addition of veliparib and carboplatin to paclitaxel followed by doxorubicin/cyclophosphamide as neoadjuvant therapy resulted in an increase in the estimated pathologic CR from 26 to 51% in triple-negative breast cancer patients \[[@B36]\]. This is currently under investigation in the Brightness study, a Phase III neoadjuvant trial comparing paclitaxel alone, with carboplatin, or with carboplatin and veliparib, followed by standard therapy with doxorubicin/cyclophosphamide (NCT02032277). These data, along with data from a Gynecologic Oncology Group study with veliparib in combination with carboplatin/paclitaxel/bevacizumab or paclitaxel/cisplatin/bevacizumab \[[@B37]\] support the tolerability and preliminary efficacy of the combination of veliparib and platinum-based chemotherapy in *BRCA* mutation carriers and in breast cancer.

A dose-escalation Phase I study of veliparib b.i.d. on days 1--7 with TMZ 150--200 mg/m^2^ once daily (q.d.) on days 1--5 defined the MTD of veliparib as 40 mg b.i.d. A Phase II trial with veliparib and TMZ in patients with metastatic breast cancer demonstrated responses in the subset of patients with a *BRCA1* or *BRCA2* mutation: total RR 25% (7/28) and CBR 50% (seven PR, seven stable disease \[SD\]) \[[@B38],[@B39]\]. Single-agent TMZ is believed to have little activity in breast cancer \[[@B40]\]. However, combination therapy with veliparib and TMZ was deemed a promising new strategy and worthy of investigation in *BRCA*-associated metastatic breast cancer.

In addition to potentiating the cytotoxic effects of multiple DNA-damaging agents, preclinical data suggest that PARP inhibitors may provide neuroprotection. Chemotherapy-induced peripheral neuropathy (CIPN) is a major toxicity of chemotherapy for which there is no approved therapy and which remains the dose-limiting toxicity for many chemotherapeutic agents \[[@B41]\]. In a diabetic rat model, treatment with PARP inhibitor attenuated pain-like behaviors, although the exact mechanism remains unknown \[[@B42]\]. Furthermore, veliparib has been shown to reduce painful neuropathy in vincristine-treated rats \[[@B43]\]. These data indicate that the therapeutic benefit of veliparib for platinum-induced neuropathy in humans should be further explored.

Based on activity observed in Phase I and Phase II clinical trials, two regimens were selected for evaluation in the presented Phase II study (TMZ with veliparib and carboplatin/paclitaxel with veliparib). The study is partially blinded to evaluate the contribution of veliparib to the safety and efficacy of the backbone regimen of carboplatin/paclitaxel. Additionally, the design allows for comparison of veliparib plus TMZ, a regimen for which nonrandomized Phase II data indicate activity, to an active comparator regimen, as TMZ alone would not be a viable comparator.

Phase II trial {#S0002}
==============

Herein we describe the design and rationale for the BROCADE study, a randomized Phase II, partially blinded, multinational, multicenter trial (EudraCT no. 2011-002913-12; NCT01506609) evaluating efficacy and tolerability of veliparib in combination with TMZ or in combination with carboplatin/paclitaxel compared with placebo plus carboplatin/paclitaxel in patients with a *BRCA1*/*2* deleterious mutation and locally recurrent or metastatic breast cancer. This study was approved by an Independent Ethics Committee/Independent Review Board before initiation and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments. All patients provided written informed consent before their participation.

Objectives {#S0003}
==========

The primary objective of this study is to determine whether veliparib in combination with TMZ or in combination with carboplatin/paclitaxel improves PFS compared with placebo plus carboplatin/paclitaxel. The secondary objectives include OS, CBR, ORR and CIPN (as assessed by the European Organization for Research and Treatment of Cancer \[EORTC\] Quality of Life Questionnaire \[QLQ\]-CIPN20 and National Cancer Institute Common Terminology Criteria for Adverse Events \[CTCAE\] 4.0 grading for peripheral neuropathy) is assessed in patients treated with veliparib plus carboplatin/paclitaxel, versus placebo plus carboplatin/paclitaxel. The tertiary objectives are to assess Eastern Cooperative Oncology Group (ECOG) performance status, quality of life and exploratory correlative endpoints.

Key eligibility criteria {#S0004}
========================

Patients aged ≥18 years with histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic, and a deleterious *BRCA1 or BRCA2* germline mutation are eligible. Patients may be enrolled on the basis of local or central results, but only patients with deleterious germline *BRCA1*/*2* mutations per the central laboratory are included in the primary analysis. Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent. If patients are *HER2+*, they must have received, and progressed on, at least one prior standard *HER2*-directed therapy, or be ineligible to receive anti-*HER2* therapy. Patients may have measurable or nonmeasurable disease; however, it must be radiologically evaluable per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 on computed tomography scan or MRI with at least one lesion outside previously irradiated areas. In addition, eligible patients are required to have ECOG performance status of 0--2, and adequate hematologic, renal and hepatic function. Patients meeting any of the following criteria are excluded: prior anticancer agent(s) or an investigational agent within 21 days of baseline (cycle 1, day 1 \[C1D1\]) or radiotherapy within 28 days prior to C1D1; more than two prior lines of cytotoxic chemotherapy for metastatic disease; prior treatment of breast cancer with TMZ, a platinum agent, or PARP inhibitor; prior taxane therapy administered for treatment of metastatic breast cancer (except patients who have undergone less than one cycle or experienced an interval of more than 1 year since treatment), and patients with history of brain metastases.

Study design & methodology {#S0005}
==========================

Eligible patients are randomized in a 1:1:1 ratio to one of three treatment arms (veliparib plus TMZ, veliparib plus carboplatin/paclitaxel, placebo plus carboplatin/paclitaxel) according to the planned schedule ([Figure 2](#F0002){ref-type="fig"}). Patients randomized to the veliparib plus TMZ treatment arm self-administer veliparib 40 mg b.i.d. days 1--7 plus TMZ 150--200 mg/m^2^ q.d. days 1--5 in each 28-day cycle. For cycle 1, the TMZ dose starts at 150 mg/m^2^ q.d. on days 1--5. If, during the first cycle, platelets (nadir) are \>100,000/μl and the absolute neutrophil count (nadir) is \>1500/μl and no grade 3 or 4 CTCAE nonhematologic toxicities attributable to TMZ are observed, the TMZ dose is escalated to 200 mg/m^2^ q.d. for cycle 2 ([Figure 3](#F0003){ref-type="fig"}). If the dose was not escalated at cycle 2, it is not escalated in future cycles. Study visits are conducted at day 1, day 15 and day 22 for the first two cycles and then day 1 of every 28-day cycle. Patients randomized to the veliparib or placebo plus carboplatin/paclitaxel treatment arms selfadminister veliparib 120 mg or placebo b.i.d. days 1--7 plus carboplatin AUC 6 administered on day 3 and paclitaxel 175 mg/m^2^ administered on day 3 of each 21-day cycle. Study visits are conducted at day 1, day 3 and day 17 of cycle 1, and day 1 and day 3 of every subsequent 21-day cycle. Patient randomization will be stratified by estrogen and/or progesterone receptor (positive or negative), prior cytotoxic therapy (yes or no), and ECOG status (0--1 or 2). Patients continue dosing until defined discontinuation criteria are met, at which time a final visit is conducted. All patients receive a follow-up visit approximately 30 days after the last dose of study treatment. Patients with controlled disease (CR, PR or SD) per RECIST 1.1 and with tolerable side effects may continue to receive treatment with veliparib plus TMZ until reaching a protocol-defined event of disease progression, experiencing unmanageable toxicity or reaching a maximum 24 cycles of veliparib plus TMZ. Patients in the veliparib or placebo plus carboplatin/paclitaxel arm with controlled disease and tolerable side effects may continue to receive treatment until reaching a protocol-defined event of disease progression or experiencing unmanageable toxicity. If both carboplatin/paclitaxel have been discontinued due to toxicity, veliparib will also be discontinued.

![**Study design scheme.**\
\*A follow-up visit does not need to be conducted if the final visit is ≥30 days after last dose of study drug. Follow-up for survival continues until death or 3 years.\
AUC: Area under the curve; b.i.d.: Twice daily; ECOG: Eastern Cooperative Oncology Group; ER: Estrogen receptor; PgR: Progesterone receptor; q.d.: Once daily; TMZ: Temozolomide.](fon-13-307-g2){#F0002}

![**Temozolomide dosing modification following cycle 1.**\
ANC: Absolute neutrophil count; CTCAE: Common Terminology Criteria for Adverse Event; Gr: Grade; TMZ: Temozolomide.](fon-13-307-g3){#F0003}

Efficacy evaluations {#S0006}
====================

PFS is assessed using modified RECIST 1.1 at 9-week intervals. In addition to being reviewed by the investigator and/or participating center staff, radiographic scans will be sent to a central imaging center (CIC) where events of disease progression will be determined. Only patients with deleterious mutations will be used in the primary and secondary efficacy analyses. Posttreatment and survival information will be collected at monthly intervals beginning on the date the patient is registered off study and for up to 3 years until the endpoint of death, the patient is lost to follow-up, or the study is terminated. CBR and ORR are assessed using RECIST 1.1. QOL data will be collected predose on C1D1, day 1 of cycle 2 and every other cycle thereafter, beginning with cycle 4, final visit and at the follow-up visit, via the EORTC QLQ C-15/BR23 scale. In addition, patients randomized to veliparib or placebo plus carboplatin/paclitaxel will complete the EORTC QLQ-CIPN20 scale.

Pharmacokinetic evaluations {#S0007}
===========================

Pharmacokinetic (PK) data are analyzed from blood samples collected at 0.5, 1, 2 and 3 h after receiving the veliparib dose. Paclitaxel pharmacokinetic sampling is carried out 2 h 55 min after start of the infusion, and free platinum (for carboplatin) sampling at 25 min after start of the infusion.

Pharmacodynamics evaluations {#S0008}
============================

Pharmacodynamics data are analyzed from blood samples collected predose and at each scheduled visit (C1D1, C2D1, D1 of every tenth cycle, and at final visit). Pharmacodynamics correlative studies are exploratory in nature. Putative biomarkers of efficacy and response may be evaluated with the goal of defining the relationship between drug concentration, PARP inhibition and disease status.

Safety evaluations {#S0009}
==================

The safety of each treatment group is assessed by evaluating study drug exposure, adverse events, serious adverse events, all deaths, changes in laboratory determinations and vital signs parameters. Patients who are randomized but did not receive study drug are not included in the safety analyses.

Sample size {#S0010}
===========

The study described herein will enroll 290 patients to accrue sufficient PFS and OS events to provide 80% power at two-sided α = 0.05 (74% at two-sided α = 0.025 for two-arm comparison) to detect a statistically significant difference between veliparib plus carboplatin/paclitaxel and placebo plus carboplatin/paclitaxel or between veliparib plus TMZ and placebo plus carboplatin/paclitaxel, assuming a true HR for PFS of 0.58 and 0.61 for OS (favoring the experimental treatment groups).

Statistical analysis methods {#S0011}
============================

All statistical analyses are determined by a two-sided p ≤ 0.05, unless otherwise noted. PFS is defined as number of days from the date the patient is randomized to the date the patient experiences an event of disease progression confirmed by the CIC, or to the date of death (all causes of mortality) if disease progression is not reached. Events of death will be included for patients who had not experienced a confirmed event of disease progression, provided the death occurred within 9 weeks of the last available disease progression assessment. Patient data will be censored at the date of last available disease progression assessment if the patient does not have a confirmed event of disease progression and the patient has not died as defined above. OS is defined as number of days from the day the patient is randomized to the date of the patient\'s death. All events of death will be included, regardless of whether the event occurs while the patient is still taking study drug, or after discontinuation. Data will be censored at the date when the patient is last known to be alive if the patient has not died. CBR at week 18 is defined as progression-free rate at 18 weeks from the Kaplan--Meier curve for time to progression (date of randomization to date of disease progression as determined by the CIC). All intention-to-treat patients will be included in the analysis. ORR is defined as proportion of patients with confirmed CR or PR per RECIST 1.1 in patients with measurable disease as determined by the CIC. All patients who had at least one measurable lesion at baseline are included in the calculation. CIPN is assessed by EORTC QLQ CIPN20 questionnaire and National Cancer Institute CTCAE 4.0 grading for peripheral neuropathy.

Interim analysis {#S0012}
================

An independent data monitoring committee reviewed unblinded safety data when approximately 36 enrolled patients met at least one of the following criteria: received two cycles of treatment, reached an event of disease progression, or discontinued the study due to toxicity/adverse events. Subsequent reviews occurred as requested by the committee. In addition, a futility analysis of veliparib with TMZ was conducted and reviewed after the week 27 tumor assessment of the first 30 patients randomized to the veliparib plus TMZ arm.

Discussion {#S0013}
==========

PARP inhibitors constitute a promising new class of targeted therapy and are actively being investigated in a number of different indications, either as single agents or in combination with various DNA-damaging therapies. The present three-arm study comparing veliparib with carboplatin/paclitaxel, placebo with carboplatin/paclitaxel and veliparib with TMZ, in locally advanced or metastatic breast cancer with deleterious *BRCA1* or *BRCA2* mutation, is based on robust preclinical data and multiple early stage clinical trials suggesting that addition of veliparib to regimens containing a platinum agent or TMZ has the potential to improve response rates compared with chemotherapy alone. Other PARP inhibitors are actively being developed as monotherapies in this indication.

Emerging evidence suggests PARP inhibitors may employ different mechanisms depending on the regimen (i.e., monotherapy vs TMZ vs platinum). Until recently, PARP inhibitor cytotoxicity in the context of impaired homologous recombination, or in combination with monofunctional alkylating agents such as TMZ or methyl methanesulfonate, was attributed to inhibition of SSBR with the resulting accumulation of SSBs and DSBs causing replication fork collapse \[[@B27],[@B44]\]. However, an additional mechanism of action of PARP inhibitors, so-called PARP trapping, has recently been described \[[@B47]\], whereby PARP inhibitors act as DNA poisons by trapping PARP on damaged DNA, resulting in cytotoxic PARP--DNA complexes. Many cellular responses are susceptible to suppression of ADP-ribosylation through PARP depletion or catalytic inhibition, whereas direct cytotoxicity via PARP trapping appears to drive both toxicity and efficacy in specific contexts, such as those where PARP inhibitors are active as monotherapy or in combination with TMZ.

In contrast, PARP trapping has remained undetectable in cells treated with platinum agents despite extensive research \[[@B23],[@B48]\]. Based on *in vitro* evidence, it has been suggested that PARP inhibitors do not substantially enhance the activity of platinum drugs \[[@B48]\]; however, recent evidence from xenograft models *in vivo* and in 3D spheroids *in vitro* clearly demonstrates that veliparib potentiates the activity of cisplatin and carboplatin \[[@B20],[@B23]\]. Consistent with the lack of detectable trapping in cisplatin-treated cells, this activity is evident at veliparib exposures sufficient for catalytic inhibition but insufficient for trapping \[[@B23]\]. These results suggest that PARP trapping does not play a role in the potentiation of platinum drug activity by PARP inhibitors, and highlights the context-specific nature of the trapping mechanism.

Another important discovery related to PARP trapping is that different PARP inhibitors display varying degrees of trapping efficiency \[[@B23],[@B47]\]. All nicotinamide adenine dinucleotide-competitive PARP inhibitors are capable of both catalytic inhibition and PARP trapping. However, lower efficiency trapping agents, such as veliparib, display trapping activity only at exposures substantially higher than those required for catalytic inhibition, while higher efficiency trapping agents such as talazoparib trap PARP at concentrations similar to those required for catalytic inhibition. To explain this phenomenon, an allosteric mechanism of trapping PARP1 at DNA SSBs was proposed \[[@B47],[@B49]\]. However, this allosteric trapping mechanism has been refuted by research performed by Hopkins *et al*. \[[@B50],[@B51]\], who demonstrated that PARP1 trapping in cells is due to inhibition of PAR synthesis, in accordance with the seminal findings of Satoh and Lindahl \[[@B52]\]. Despite extensive efforts in multiple systems, the authors detected no evidence of an allosteric mechanism. The underlying cause for the substantial variation in trapping efficiency among PARP inhibitors remains to be elucidated.

Categorizing PARP inhibitors according to PARP trapping potency has been proposed \[[@B48]\], on the basis that this broad variance in trapping efficiency is likely to affect the suitability of a PARP inhibitor for a specific regimen. Based on *in vitro* evidence, it has been suggested that high-efficiency trapping agents are preferable to veliparib in combination with TMZ and other alkylating agents \[[@B48],[@B49]\]. However, more-recent evidence suggests the toxicity associated with PARP trapping is dose limiting in preclinical *in vivo* models \[[@B51]\]. As a result, more-potent trapping is not associated with superior efficacy when PARP inhibitors are combined with TMZ at MTDs \[[@B50]\]. In support of this lack of association, veliparib strongly potentiated TMZ in a murine melanoma model, with maximal efficacy achieved at a dose as low as 25 mg/kg/day \[[@B20]\].

The impact of trapping efficiency on the clinical activity of different PARP inhibitors remains an area of ongoing investigation. While there is currently no direct evidence of PARP trapping in patients treated with PARP inhibitors, there is considerable correlative evidence that the PARP trapping mechanism is clinically relevant. First, trapping is detectable *in vitro* at concentrations consistent with clinical exposures \[[@B47]\]. In addition, PARP trapping activity has been associated with greater cytotoxicity toward myeloid and erythroid progenitors \[[@B23]\], suggesting that trapping may contribute to the anemia and myelosuppression observed in some patients treated with PARP inhibitors. Consistent with this, the combination of PARP inhibitors with TMZ in the clinic has required substantial reductions in the dose of PARP inhibitor relative to the monotherapy RP2D, in large part because of exacerbation of neutropenia and thrombocytopenia typically associated with TMZ \[[@B38],[@B53]\]. This effect appears to be less pronounced in contexts where trapping may be less relevant, such as regimens containing platinum agents. Indeed, in the present study the veliparib RP2D employed in the carboplatin/paclitaxel arm (120 mg b.i.d.) is substantially greater than that in the TMZ arm (40 mg b.i.d.). In the monotherapy setting, clinical plasma exposures at the RP2D of different PARP inhibitors are more strongly correlated with trapping efficiency than catalytic inhibition potency. These observations suggest that toxicity associated with PARP trapping may be dose limiting. Additional clinical data are needed to assess whether there is a correlation between trapping efficiency and clinical activity of monotherapy PARP inhibition in homologous recombination-deficient tumors.

Overall, these observations suggest that catalytic inhibition and PARP trapping may act differentially to impact efficacy and toxicity, depending on the specific therapeutic combination. A PARP inhibitor such as veliparib, with a dose/concentration window that allows for robust catalytic inhibition at doses that do not engage significant trapping activity, may provide for enhanced combination utility and an improved therapeutic window in combination regimens (e.g., with platinum agents) where a trapping mechanism of action is not required \[[@B22],[@B54]\].

Improving our understanding of the mechanisms of resistance to PARP inhibitors is also a crucial area of research. Single-agent studies of veliparib in *BRCA*-mutated breast cancer demonstrate a 40--60% ORR at the RP2D, which suggests substantial primary resistance, even in this population of patients sensitive to PARP inhibition \[[@B25],[@B56]\]. Furthermore, a substantial proportion of cancers develop resistance to treatment following an initial response. Preclinical data suggest that resistance to PARP inhibition can be created in cell lines through constant high-level exposure to PARP inhibitors and the development of PARP inhibitor-resistant clones \[[@B57]\]. Resistance also appears to be context dependent. Clinical trial data in ovarian cancer suggest that resistance to platinum agents also decreases sensitivity to PARP inhibition \[[@B58]\]. This cross-resistance between PARP inhibitor and platinum therapy can partly be attributed to genetic reversion that corrects, or bypasses, the original *BRCA1*-inactivating mutation \[[@B59]\]. A recent study also demonstrated *BRCA2* secondary mutations in PARP inhibitor-resistant tumor cells that restored *BRCA2* function, thereby conferring resistance \[[@B60]\].

In conclusion, the BROCADE trial described will investigate the efficacy and tolerability of veliparib with TMZ, an all-oral regimen or veliparib with carboplatin/paclitaxel compared with placebo with carboplatin/paclitaxel in patients with *BRCA1*/*2* mutation and metastatic breast cancer. The results of this trial will provide valuable clinical data in the quest to realize the full potential of PARP inhibitors, with the objective of ultimately improving clinical outcomes.

###### EXECUTIVE SUMMARY

**Background** {#S0014}
--------------

-   PARP inhibitors block DNA damage repair and may thereby enhance the clinical activity of DNA-damaging chemotherapy.

-   Deleterious mutation in *BRCA1* or *BRCA2* impairs homologous recombination DNA repair, rendering cancers with such mutations uniquely sensitive to platinum and PARP inhibitor therapy.

-   PARP inhibitors are being investigated in numerous clinical trials across several indications, including *BRCA1*/*2*-mutated breast cancer.

**Veliparib** {#S0015}
-------------

-   Veliparib is an orally available PARP inhibitor that potentiates the antitumor activity of DNA-damaging therapies, including temozolomide (TMZ) and platinum agents, in preclinical models.

-   Based on the results of early phase clinical trials, TMZ with veliparib and carboplatin/paclitaxel with veliparib were selected as regimens for evaluation in this Phase II study.

**Phase II trial** {#S0016}
------------------

-   The primary objective of this study is to determine whether veliparib, in combination with TMZ or with carboplatin/paclitaxel, improves progression-free survival relative to placebo plus carboplatin/paclitaxel.

-   The secondary objectives include overall survival, clinical benefit rate and overall response rate.

**Key eligibility criteria** {#S0017}
----------------------------

-   Patients with histologically confirmed locally recurrent or metastatic breast cancer harboring a deleterious *BRCA1* or *BRCA2* germline mutation.

-   No prior treatment of breast cancer with TMZ, platinum or PARP inhibitor therapy.

-   No more than two lines of chemotherapy for advanced breast cancer.

-   No CNS metastases.

**Study design & methodology** {#S0018}
------------------------------

-   Eligible patients are randomized 1:1:1 to veliparib plus TMZ, veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel.

**Efficacy, pharmacokinetic & safety evaluations** {#S0019}
--------------------------------------------------

-   For progression-free survival, clinical benefit rate and overall response rate, tumors are assessed using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 at 9-week intervals.

-   Pharmacokinetic data are analyzed from blood samples collected at defined time points after dosing.

-   Safety is assessed by evaluating study drug exposure, adverse events, serious adverse events, deaths, changes in laboratory values and vital sign parameters.

**Discussion** {#S0020}
--------------

-   The clinical efficacy of PARP inhibitors, as single agents and in combination with DNA-damaging therapies, is being investigated in clinical trials.

-   The mechanism of action responsible for PARP inhibitor antitumor activity is likely to be context dependent, and includes both the potentiation of DNA damage following inhibition of poly(ADP-ribose) synthesis (catalytic inhibition) and the direct cytotoxicity of PARP inhibitor-induced PARP--DNA complexes (PARP trapping).

-   Various PARP inhibitor resistance mechanisms, some common to platinum resistance, are indicated by preclinical and clinical studies.

-   The results of this trial will provide valuable clinical data on the effectiveness of the PARP inhibitor veliparib in *BRCA1*- or *BRCA2*-mutated breast cancer in combination with DNA-damaging therapies.
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